Equal access to COVID-19 vaccines could be worth billions

Equal access to COVID-19 vaccines could be worth billions

By averting economic disaster and helping to end the pandemic, 10 major economies could be $466 billion better off by 2025, new data finds.

This is 12 times the $38 billion estimated cost of the Access to COVID-19 Tools (ACT) Accelerator.

The collaboration was launched in April by the World Health Organization and its partners to support the development and equitable distribution of COVID-19 tests, treatments and vaccines.



Making sure everyone has equal access to COVID-19 vaccines could be worth more than $460 billion to 10 major economies by 2025, according to a new report.

Data shows that leaving low- and lower-middle-income countries without access to vaccines amid the COVID-19 pandemic will cause significant economic damage for all economies and put "decades of economic progress“ at risk.

Commissioned by the Bill & Melinda Gates Foundation and compiled by Eurasia Group, a political risk research and consulting firm, the data assesses the economic benefits to advanced economies of contributing to the work of the Access to COVID-19 Tools (ACT) Accelerator.



The ACT-Accelerator is a collaboration launched in April by the World Health Organization (WHO) and its partners to support the development and equitable distribution of COVID-19 tests, treatments and vaccines.